BRMN

5 Biotech Stocks to Buy for a Strong Growth Prognosis

By Aaron Levitt, InvestorPlace Contributor
The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

By Karl Utermohlen, InvestorPlace Writer
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.

Trade of the Day: Will This Orphan Drug Stock be at Home in Your Portfolio?

By Sam Collins, InvestorPlace Chief Technical Analyst
BioMarin Pharmaceutical Inc. (BMRN) could land speculators 20% returns.

BioMarin (BMRN) Stock Soars, Taking IBB With It

By John Divine, InvestorPlace Assistant Editor
BioMarin (BMRN) stock is soaring on Thursday after promising Phase 2 trial data on a dwarfism drug, vosoritide. The IBB ETF is rallying, too.